Advisory Board

Our InsuLife team brings a powerful combination of proven commercial, strategic and scientific capabilities.

Prof. Dr. Howard Maibach

Dr. Maibach is considered one of the prominent dermatologists in the world and is co-author of more than 1400 scientific publications. He is a Professor in dermatology at the University of California, San Francisco. Dr. Maibach has served on the editorial boards of more than 30 scientific journals. He is a member of 19 professional societies, including the American Academy of Dermatology, San Francisco Dermatological Society and International Commission on Occupational Health.

Hans Othar Blix

Hans is an investor and has been working in the field of business development for more than 25 years. He has served as a consultant or board member in more than fifty companies across Europe and the US. Hans has broad international business experience and has expertise in investor relations, IPOs, private placements, mergers & acquisitions, restructuring, distressed situations, finance, strategic planning and execution, investor negotiations, venture funds, and exits. Hans holds a Master of Business and Marketing from the Oslo Business School in Norway as well as a degree in computer science from EDB Høyskolen in Oslo, Norway. He currently resides in Boca Raton, Florida.

Harry J. Rodriguez

Harry is a respected strategy-driven international finance professional with a successful track record in navigating uncertainty, identifying opportunities, and implementing effective strategies and controls in Developed and Emerging markets. He has over 30 years of leadership and C-Suite level experience in  banking, risk management, and lending covering the United States, Latin America, Asia, the Caribbean, Europe and Northern Africa. 
Harry has a Mechanical Engineering Degree from Rensselaer Polytechnic Institute (New York) and a Master of Business Administration from the Simon Business School at the University of Rochester (New York).

Pål Falck, PhD, MBA

MBA, PhD in Clinical Nephrology focused Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway. Pål is the Chief Business Officer at Oncorena AB and a Board Member of University of Oslo, Department of Pharmacy.

Roy Waldron

Roy F. Waldron served as the Senior Vice President, Associate General Counsel and Chief Intellectual Property Counsel at Pfizer for almost twenty years (retired June 2018), where he led global teams of Pfizer attorneys and professionals in procuring patents, and worked closely with R&D, licensing and business development and Pfizer business units to develop and strengthen intellectual property strategies for products in development. 

Mr. Waldron currently sits on the boards of several pharmaceutical startups and non-profit organizations.  He holds a JD from New York University Law School, a PhD from Yale and a BA from Dartmouth College.

David Weild IV

David Weild is a noted expert on capital markets and capital formation who has testified before the U.S. Congress at the House Subcommittee on Capital Markets and Government Sponsored Enterprises, the SEC, and in front of the 34-member nations and the European Commission for the Organization of Economic Co-operation and Development (OECD). 

Mr. Weild has served as Vice Chairman of The NASDAQ Stock Market in charge of the Corporate Client Division with line responsibility for NASDAQ's 4,000 listed companies.  He created NASDAQ's Market Intelligence Desk, Corporate Services Network and dual listings strategy which ultimately resulted in listing Charles Schwab and Hewlett Packard.  While at NASDAQ, Mr. Weild had the privilege of working with such luminaries as Howard Schultz (Starbucks), Tom Stemberg (Staples), Craig Barrett (Intel), Michael Dell (Dell Computer), Steve Jobs (Apple, Pixar, NeXT Computer) and others. 

Mr. Weild headed equity capital markets and corporate finance at a top-ten underwriter of IPOs and follow-on equity offerings.  During his career, he has participated in managing more than 1,000 public equity offering transactions. 

Mr. Weild holds an MBA from the Stern School of Business and a B.A. degree from Wesleyan University.  He also studied on exchange at The Sorbonne, Ecole des Haute Etudes Commerciales, and The Stockholm School of Economics.  Mr. Weild is former Treasurer of The Bond Club of New York.  David holds FINRA Series 7, 24, 63, 79, 82 and 99 licenses.

InsuLife is a Norwegian company aiming at bringing the unparalleled developmental Levellor™ spray-based insulin to market.
Learn More
© Copyright 2022 - InsuLife AS, All Rights Reserved